tepotinib: Clinical Trials

15 trials of tepotinib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 4 recruiting, 3 unknown, 2 active not recruiting. 15 Phase 2, 6 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 215Completed 4, Recruiting 4, Unknown 3, Active not recruiting 2, Terminated 2
Phase 16Completed 3, Active not recruiting 1, Terminated 1, Unknown 1

Follow tepotinib: new trials by email Literature Review of tepotinib trials Research Report on tepotinib

Trials (filtered) newest first · largest first

All 15 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Biospecimen Collection, Computed Tomography, Lymphoscintigraphy - Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Phase 2RecruitingSWOG Cancer Research Network562024-08-082026-10-09
PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer
Amivantamab, Tepotinib - Non-small Cell Lung Cancer
Phase 1 / Phase 2Active not recruitingM.D. Anderson Cancer Center32024-06-182026-09-11
Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment
Lazertinib, Tepotinib - Non-Small Cell Lung Cancer Metastatic
Phase 2RecruitingSehhoon Park472024-06-112026-09-10
CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC
Tepotinib - Advanced Non-Small Cell Lung Cancer With MET Mutations
Phase 1 / Phase 2TerminatedCriterium, Inc.22022-05-252023-10-18
Tepotinib Plus Paclitaxel in MET Amplified or MET Exon 14 Alterated Gastric and GEJ Carcinoma
Tepotinib plus paclitaxel - Gastric Cancer, Gastroesophageal-junction Cancer
Phase 1 / Phase 2UnknownHallym University Medical Center422022-03-012022-07-05
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
Alectinib, Cobimetinib, Vismodegib - Advanced Cancer, Solid Tumor
Phase 2RecruitingHelsinki University Central Hospital2502021-12-102026-11-10
Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)
Tepotinib, Cetuximab - Colorectal Neoplasms
Phase 2TerminatedEMD Serono Research & Development Institute, Inc.32021-01-282022-12-22
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy
Erlotinib, Trastuzumab, Trastuzumab emtansine - Breast Cancer, Gastrointestinal Cancer
Phase 2UnknownFondazione per la Medicina Personalizzata4002020-10-072023-10-03
Tepotinib in Solid Tumors Harboring MET Alterations
Tepotinib - Solid Tumor, MET Exon 14 Skipping Mutation
Phase 2UnknownChungbuk National University Hospital1002020-01-162020-12-02
A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)
Tepotinib, Osimertinib - Non-small Cell Lung Cancer
Phase 2CompletedEMD Serono Research & Development Institute, Inc.1402019-09-192026-08-21
Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)
Tepotinib - Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification, Lung Adenocarcinoma Stage IIIB/IV
Phase 2Active not recruitingEMD Serono Research & Development Institute, Inc.3372016-09-132026-07-14
The Drug Rediscovery Protocol (DRUP Trial)
Panitumumab, Olaparib, Dabrafenib - Cancer, Tumors
Phase 2RecruitingThe Netherlands Cancer Institute15502016-08-012024-01-24
c-Met Second-Line Hepatocellular Carcinoma
Tepotinib - Carcinoma, Hepatocellular
Phase 1 / Phase 2CompletedMerck KGaA, Darmstadt, Germany662014-05-182022-08-24
Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma
Tepotinib 300 mg, Tepotinib 500 mg, Tepotinib 1000 mg - Carcinoma, Hepatocellular
Phase 1 / Phase 2CompletedMerck KGaA, Darmstadt, Germany1172014-01-062022-08-24
Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)
Tepotinib, Gefitinib, Pemetrexed - Non-small Cell Lung Cancer
Phase 1 / Phase 2CompletedMerck KGaA, Darmstadt, Germany882013-12-232022-11-08

Conditions studied

Carcinoma, Non-Small-Cell Lung (7)  ·  Neoplasms (3)  ·  Carcinoma, Hepatocellular (2)  ·  Adenocarcinoma (1)  ·  Breast Neoplasms (1)  ·  Colorectal Neoplasms (1)  ·  Deafness, Autosomal Recessive 39 (1)  ·  Gastrointestinal Neoplasms (1)  ·  Hematologic Neoplasms (1)  ·  Lung Neoplasms (1)  ·  Stomach Neoplasms (1)

Sponsors

EMD Serono Research & Development Institute, Inc. (3)  ·  Merck KGaA, Darmstadt, Germany (3)  ·  Chungbuk National University Hospital (1)  ·  Criterium, Inc. (1)  ·  Fondazione per la Medicina Personalizzata (1)  ·  Hallym University Medical Center (1)  ·  Helsinki University Central Hospital (1)  ·  M.D. Anderson Cancer Center (1)  ·  SWOG Cancer Research Network (1)  ·  Sehhoon Park (1)  ·  The Netherlands Cancer Institute (1)

Countries

South Korea (7)  ·  United States (6)  ·  Italy (5)  ·  China (4)  ·  Spain (4)  ·  Taiwan (4)  ·  Belgium (3)  ·  France (3)  ·  Germany (3)  ·  Netherlands (3)  ·  Japan (2)  ·  Malaysia (2)  ·  Russia (2)  ·  Singapore (2)  ·  Austria (1)

Top investigators

Andrea Botticelli (1)  ·  Dae Young Zang, Dr (1)  ·  David R Camidge, MD, PhD (1)  ·  E.E. Voest, prof. (1)  ·  Katriina Jalkanen, MD, PhD (1)  ·  Ki Hyeong Lee, M.D. (1)  ·  Paolo Marchetti (1)  ·  Paul K Paik (1)  ·  Sehhoon Park (1)  ·  Tejas Patil, MD (1)  ·  Xiuning Le, MD,PHD (1)

Results publications

PMID 35771259, PMID 32469185, PMID 32479794, PMID 33824476, PMID 33972742, PMID 35086719, PMID 35385993, PMID 35598186, PMID 36101520, PMID 36870947, PMID 36999526, PMID 37270698, PMID 37424386, PMID 37944528, PMID 38575731, PMID 38630551, PMID 40880848, PMID 41023484, PMID 41963505, PMID 41986720

NIH funding

2015 (1), 2016 (1), 2018 (1), 2019 (1), U10CA180888 (1)